[1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003; 2:104-113]Search in Google Scholar
[2. Hechtman L. Assessment and diagnosis of attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000; 9:481-49810.1016/S1056-4993(18)30102-0]Search in Google Scholar
[3. Dell’Agnello G, Maschietto D, Pancotto A, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Escobar R, Zuddas A. Atomoxetine hydrochloride in the treatment of children and adolescents with attentiondeficit/ hyperactivity disorder and comorbid oppositional defiant disorder: Results from a placebo-controlled Italian study. Eur Neuropsychopharmacol. 2009; 19: 822-83410.1016/j.euroneuro.2009.07.008]Search in Google Scholar
[4. Pactl et al. Hyperkinetická porucha a poruchy chování. 1st ed. Praha: Grada Publishing.2007; 240s.]Search in Google Scholar
[5. Aosaki T, Graybiel AM, Kimura M. Effect of the nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkeys.Science. 1994; 265:412-41510.1126/science.8023166]Search in Google Scholar
[6. Goldman-Rakic PS. Working memory dysfunction in schizophrenia.J Neuropsychiatry Clin Neurosci. 1994;6:348-35710.1176/jnp.6.4.348]Search in Google Scholar
[7. Sawaguchi T, Matsumura M, Kubota K: Catecholaminergic effects on neuronal activity related to a delayed response task in monkey prefrontal cortex.J Neurophysiol.1990; 63:1385-140010.1152/jn.1990.63.6.1385]Search in Google Scholar
[8. Aston-Jones G, Bloom FE: Norepinephrine containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli.J Neuroscience.1981;1:887-90010.1523/JNEUROSCI.01-08-00887.1981]Search in Google Scholar
[9. MTA Cooperative Group.Arch Gen Psychiatry. 1999; 56: 1073-86]Search in Google Scholar
[10. Conley R, Gupta SK, Sathya G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form.Curr Med Res Opin. 2006; 22(10):1879-9210.1185/030079906X132613]Search in Google Scholar
[11. Volkow N. et al. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry. 1999; 156 (1):19-2610.1176/ajp.156.1.19]Search in Google Scholar
[12. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998; 94: 127-5210.1016/S0166-4328(97)00175-7]Search in Google Scholar
[13. Wigal S B. Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults, CNS Drugs. 2009; 23 (1): 21]Search in Google Scholar
[14. Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorderacross the lifespan: the child, adolescent, and adult. Dis Mon .2007; 53 (2): 70-13.10.1016/j.disamonth.2007.01.00117386306]Search in Google Scholar
[15. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005; 90:26-9.10.1136/adc.2004.059386]Search in Google Scholar
[16. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology.2002; 27(5): 699-71.110.1016/S0893-133X(02)00346-9]Search in Google Scholar
[17. Gehlert DR, Schober DA, Gackenheimer SL. Comparison of (R)-[‘H]tomoxetine and (R/S)-[‘H]nisoxetine binding in rat brain. J Neurochem. 1995; 64 (6): 2792-800.10.1046/j.1471-4159.1995.64062792.x7760060]Search in Google Scholar
[18. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003; 26(10): 729-40.10.2165/00002018-200326100-0000612862507]Search in Google Scholar
[19. Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attentiondeficit/ hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol. 2007; 17(5): 689-700.10.1089/cap.2006.010017979588]Search in Google Scholar
[20. Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidat on sleep in children with ADHD. Sleep. 2006; 29(12): 1573-85.10.1093/sleep/29.12.157317252888]Search in Google Scholar
[21. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003; 13: 53-63.10.1089/10445460332166619912804126]Search in Google Scholar
[22. Eli Lilly and Company. Atomoxetine (Strattera™) prescribing information [online]. Available from URL: http://pi.lilly.com/tis/strattera-pi.pdf [Accessed 2009 Feb 9].]Search in Google Scholar
[23. Sauer J.M., Ring B.J., Witcher J.W. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005; 44:571-590.10.2165/00003088-200544060-0000215910008]Search in Google Scholar
[24. Michelson D. et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007; 68:582-587.10.4088/JCP.v68n0414]Search in Google Scholar
[25. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee RF, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D.Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry.2002;159:1896-190110.1176/appi.ajp.159.11.189612411225]Search in Google Scholar
[26. Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001; 40:147-15810.1097/00004583-200102000-0000911211363]Search in Google Scholar
[27. Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1197; 36:1715-172510.1097/00004583-199712000-000209401333]Search in Google Scholar
[28. Raine A, Venables PH, Williams M. Relationships between central and autonomic measures of arousal at age 15 years and criminality at age 24 years. Arch Gen Psychiatry. 1990;47:1003-7.10.1001/archpsyc.1990.018102300190032241502]Search in Google Scholar
[29. AACAP Official Action.. Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. J Am Acad Child Adolesc Psychiatry. 1997:36:122-39.]Search in Google Scholar
[30. Lahey BB, Hart EL, Pliszka S, Applegate B, McBurnett K. Neurophysiological correlates of conduct disorder: a rationale and a review. J Clin Child Psychol. 1993;22:141-53.10.1207/s15374424jccp2202_2]Search in Google Scholar
[31. Masi G, Manfredi A, Milone A. Predictors of nonresponse to psychosocial treatment in children and adolescents with disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2011; 21:51-55.10.1089/cap.2010.003921309697]Search in Google Scholar
[32. American Academy of Child & Adolescent Psychiatry (AACAP). Preventive effects of treatment of disruptive behavior disorder in middle childhood on substance use and delinquent behavior. Journal of the American Academy of Child and Adolescent Psychiatry. 2007; 46 (1): 33-39.10.1097/01.chi.0000246051.53297.5717195727]Search in Google Scholar
[33. Sondeijker FEPL, Ferdinand RF, Oldehinkel AJ, Veenstra R, De Winter AF, Ormel J, Verhulst FC. Classes of adolescentswith disruptive behaviors in a general population sample. Soc Psychiatry Psychiatr Epidemiol. 2005; 40:931-93810.1007/s00127-005-0970-616222441]Search in Google Scholar
[34. Burns GL, Walsh JA. The influence of ADHD-hyperactivity/ impulsivity symptoms on the development of oppositional defiant disorder symptoms in a 2-year longitudinal study. J Abnorm Child Psychol. 2002; 30:245-25610.1023/A:1015102812958]Search in Google Scholar
[35. Chen TJH, Blum K, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J, Downs BW, Comings DE. Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of “super normal controls” in psychiatricgenetic research of complex behavioral disorders. Med Hypotheses. 2005;65:703-70710.1016/j.mehy.2005.04.03715964153]Search in Google Scholar
[36. Comings DE, Chen C, Wu S, Muhleman D. Association of the androgen receptor gene (AR) with ADHD and conduct disorder. Neuroreport. 1999; 10:1589-159210.1097/00001756-199905140-0003610380986]Search in Google Scholar
[37. Oosterlaan J, Scheres A, Sergeant JA.Which executive functioning deficits are associated with AD/HD, ODD/CD and comorbid AD/HD+ODD/CD? J Abnorm Child Psychol.2005; 33:69-8510.1007/s10802-005-0935-y15759592]Search in Google Scholar
[38. Baving L, Rellum T, Kaucht M, Schmidt MH.Children with oppositional-defiant disorder display deviant attentional processingindependent of ADHD symptoms. J Neural Transm.2006;113:685-6910.1007/s00702-005-0345-x16082512]Search in Google Scholar
[39. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M: Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry.2001;40:168-17910.1097/00004583-200102000-0001111211365]Search in Google Scholar
[40. Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L; Atomoxetine ADHD/ODD Study Group: Atomoxetine for the treatment of attentiondeficit/ hyperactivity disorder and oppositional defiant disorder. Pediatrics.2008; 121:314-2010.1542/peds.2006-188018245404]Search in Google Scholar
[41. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebocontrolled trial. Pediatrics.2004; 114(1):1-810.1542/peds.114.1.e115231966]Search in Google Scholar
[42. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004; 8:45-5210.1177/10870547040080020215801334]Search in Google Scholar
[43. Newcorn J, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attentiondeficit/ hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry.2005; 44:240-24810.1097/00004583-200503000-0000815725968]Search in Google Scholar
[44. Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, Witte MM: Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: A meta-analysis of controlled clinical trial data. Psychopharmacology.2007; 190:31-4110.1007/s00213-006-0565-217093981]Search in Google Scholar
[45. Anderson et al. Arch Gen Psychiatry.1987; 44(1):69 -7610.1001/archpsyc.1987.018001300810102432848]Search in Google Scholar
[46. Jennifer SB, Mark RD . Examining Alternative Explanations of the Covariation of ADHD and Anxiety Symptoms in Children. A Community Study J Abnorm Child Psychol. 2008; 36:67-7910.1007/s10802-007-9160-117636434]Search in Google Scholar
[47. Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. Journal of American Academy of Child & Adolescent Psychiatry.1989; 28:882-88710.1097/00004583-198911000-000122808258]Search in Google Scholar
[48. Costin J, Vance A, Barnett R, O’Shea M, Luk E. Attention deficit hyperactivity disorder and comorbid anxiety: Practitioner problems in treatment planning. Child & Adolescent Mental Health, 2002; 7:16-2410.1111/1475-3588.00005]Search in Google Scholar
[49. Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M. Which boys respond to stimulant medication? A controlled trial of MPH in boys with disruptive behavior. Psychol Med.1987;17:121-14310.1017/S0033291700013039]Search in Google Scholar
[50. Diamond IR, Tannock R, Achachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry. 1999; 38:402-40910.1097/00004583-199904000-0001210199111]Search in Google Scholar
[51. Kratochvil, Newcorn, Arnold L, Duesenberg, Emslie, Quintana, Sarkis, Wagner, GaoAO, Michelson, Biederman. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety aymptoms. J. Am. Acad. Child Adolesc. Psychiatry. 2005; 44(9): 915-24]Search in Google Scholar
[52. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology. 2007; 194:197-20910.1007/s00213-007-0840-x17572882]Search in Google Scholar
[52. Geller, Donnelly, Lopez, Rubin, Newcorn, Sutton, Bakken, Packowski, Kelsey, Sumner. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J. Am. Acad. Child Adolesc Psychiatry. 2007;46(9): 111910.1097/chi.0b013e3180ca838517712235]Search in Google Scholar
[53. Milberger S, Biederman J, Faraone SV, Murphy J, Tsuang MT. Attention deficit hyperactivity disorder and comorbid disorders: Issues of overlapping symptoms. American Journal of Psychiatry.1995; 152: 1793-179910.1176/ajp.152.12.17938526248]Search in Google Scholar